Katherine A. Eade insider trades
Open-market stock purchases and sales by Katherine A. Eade, Director at Harvard Bioscience Inc, from SEC Form 4 filings since Oct 30, 2017.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +243%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jun 9, 2026 | HBIO Harvard Bioscience Inc | Bought (not open market) | — |